F-D-C Reports, Windhover Information and Boston Healthcare Associates proudly present:

How To Maximize Your Reimbursement Value Through Pharmacoeconomic and Outcomes Research

Adapting to the Changing Dossier Environment
Presented by:

 

For more information on Windhover products and conferences, visit us at www.windhover.com,
or
send an email to conferences@windhover.com.
10 Hoyt St., Norwalk, CT 06851
* Tel: +1 (203) 838-4401 x 113
* Fax: +1 (203) 838-3214

Thursday, June 26, 2008 • 12 PM ET / 9 AM PT • 90 minutes

About the event • Key topics • Speakers • Benefits • Register

Featuring

Scott Steinke
Pharma Executive Editor, FDC Reports
(moderator)

Gina Ford
Executive Director, Boston Healthcare

Phil Cyr
Director, Boston Healthcare

  • Live webinar: $399
  • Live webinar plus complete audio recording: $499
  • Audio recording only: $499

A recent survey of health plan pharmacy directors indicated that they felt that more than half of the economic models submitted as part of the AMCP were inadequate. In addition, WellPoint’s Outcomes-based Formulary(SM) Guidelines, which were heavily influenced by international health technology assessment organizations such as NICE and the Australian Technology Assessment Agencies, have drastically increased health economic and outcomes evidentiary requirements for new drug submissions.

US health care payers have increased their efforts to incorporate pharmacoeconomic and health outcomes data into their coverage and formulary decisions. In addition to budget-impact, quality-of-life, and cost-of-illness information for your new products, the AMCP dossier is now emphasizing the need for greater transparency of health economic and outcomes data submitted, especially cost-effectiveness models.

But what are the health economics and outcomes research changes to the AMCP dossier? What are the key evidentiary requirements of WellPoint’s Outcomes-based Formulary(SM) Guidelines? Find out exactly what you need to know about these changes before it’s time to submit your next drug for approval.

Join us for a thought-provoking analysis. Grab your team (or several teams), a conference room at your office, a phone and a computer with Web access (that last one's optional). No travel required.

Back to top

Walk away with valuable answers to the following questions:

  • How do you conduct the right pharmacoeconomic and health outcomes analyses for your new products?
  • What are the evidentiary requirements of the AMCP and WellPoint dossiers related to health economics and outcomes research?
  • What are some “real-world” examples of the impact pharmacoeconomic information will have on payers’ decisions?
  • How do U.S. pharmacy and medical directors use pharmacoeconomic and outcomes research in their decision-making process?
  • How do you maximize your reimbursement value through pharmacoeconomic and outcomes research?
  • How will U.S. payers use pharmacoeconomic and outcomes research in the coming years?
  • Which pharmacoeconomic studies are most commonly used for payer coverage and formulary decisions, and what you should know about them?
  • How are private health plans using pharmacoeconomic information?
  • What role will pharmacoeconomics and outcomes research play in the public payer sector?

…and more!

Back to top

 

 

Gina Ford
Executive Director
Boston Healthcare

Ms. Ford develops commercialization and reimbursement strategies for specialty products facing unique access situations. She has 15 years of health care experience, and most recently has worked in preparing specialty products for commercial launch. Ms. Ford was a Senior Director of Reimbursement for a specialty pharmaceutical company where she led field teams to create favorable payer policies and internal hotline teams for best practice claims management. Her leadership has resulted in the commercial launch of two specialty products through the development and implementation of payer strategy across multiple payer segments.

Prior to entering the specialty pharmaceutical industry, Ms. Ford was a clinical pharmacist and served as the Executive Director for the International Academy of Compounding Pharmacists, responsible for the implementation of the pharmaceutical compounding section of the FDA Modernization Act of 1997 in collaboration with Congress and FDA. In 2000, Ms. Ford received Drug Topics magazine's "Pharmacist of the Year" award recognizing her contributions to women's health care and design of a novel distribution network in menopause management.

Ms. Ford received her BS in Pharmacy from Southwestern Oklahoma State University and her MBA from Capella University.

 

 

Phil Cyr
Director
Boston Healthcare

Mr. Cyr develops and conducts health economics and outcomes research for reimbursement strategies for biopharmaceutical, medical device and diagnostic products. He has 13 years of health care experience in health economics and outcomes research and developing business strategies for established and emerging life sciences organizations.

Mr. Cyr has conducted health policy and pharmacoeconomic research in both industry and academic environments, including multi-centered research collaborations involving academic medical centers and major pharmaceutical companies. His research spans many therapeutic areas including cancer, hypertension, diabetes, CNS, autoimmune diseases and infectious disease.

Mr. Cyr holds an A.B. in Biology and History from Kenyon College and a M.P.H. with a concentration in Epidemiology and Biostatistics from Boston University School of Public Health. In addition, he has been Adjunct Professor at the George Mason School of Management (Bioscience Management Program).

Back to top

What does registration get me?
  • One (1) phone line, for you alone, or around which to gather your team(s). Toll-free in the U.S. only.
  • One (1) password to a website on which you'll be taken through the presenter's slides as they speak to them.
  • An interactive Q&A round with speakers: Type your questions on the website during the presentation, for the speakers to address afterward.
  • Online access to the audio and slides of the entire event if you can't attend the webinar live, and still want to hear the content.
  • The insight you've come to expect and respect from Windhover and our guest speakers.
What are the unique benefits of a webinar?
  • Lower cost and, therefore, higher value. Your entire team can listen in one room.
  • No travel required. You just have to walk to your conference room.
  • A team approach. You've often wanted to have everyone on your team getting the same knowledge and insight you derive from physical conferences. Now you can.
  • Interactivity. You're remote, but not removed. Our webinars let you ask the important, burning, controversial questions of our speakers that you'd be able to pose at a physical conference.
  • Flexibility. Want to be able to review what you learn? No problem ... just register for the live webinar PLUS a digital copy of the entire event to listen to at your convenience. Interested in the topic but have a scheduling conflict? Don't worry — the recording is available for purchase at any time!

Back to top

Back to top